Follow-up Survey - Ushering in a New Era of Sustainable Weight Loss with Incretin-Based Therapies

LIVE EVENT OCCURRED ON MARCH 20, 2021

  •  The metabolic adaptation in obesity
  •  The value of sustained weight loss and related complications
  •  The latest evidence for incretin-based therapies for long-term weight management

This course is a virtual live CME-certified Ancillary Symposium developed in collaboration with our partner - Clinical Care Options (CCO) to be presented at ENDO 2021. This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc. This ancillary symposium is developed through the Endocrine Society’s Special Programs Committee (SPC).

PLEASE CLICK "START" TO COMPLETE FOLLOW-UP SURVEY

Learning Objectives

Upon successful completion of the activities, participants should be better able to:

  • Examine the metabolic adaptations that contribute to weight loss challenges in patients with obesity
  • Describe the physiologic and metabolic effects of incretin-based therapies that lead to weight loss in patients with obesity and the benefits of sustained weight loss on obesity- related comorbidities
  • Summarize the long-term efficacy and safety data of current and emerging incretin-based therapies for the treatment of patients with obesity

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Medical Knowledge
Topic Area: 
Obesity
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Course opens: 
05/20/2021
Course expires: 
12/31/2021
Rating: 
0

FACULTY

Kristina M. Utzschneider, MD
Associate Professor of Medicine
University of Washington
Seattle, WA

Randy J. Seeley, PhD
Professor of Surgery
University of Michigan
Ann Arbor, MI

Jenny Tong, MD, MPH
Associate Professor of Medicine
Division of Metabolism, Endocrinology and Nutrition
University of Washington
Seattle, WA

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
Amy E. Rothberg, MD, PhD: Spouse, Consultant of Merck
Randy J. Seeley, PhD: Consulting Fee, Novo Nordisk, Sanofi-Aventis, Kintai, Scohia, Eli Lilly & Company, Ionis Pharmaceuticals Inc.; Grant Recipient, AstraZeneca, Novo Nordisk, Pfizer Global R&D, Kintai, Energesis; Stock Owner, Zafgen, Calibrate Health, Rewind Health.

The following faculty reported no relevant financial relationships: 
Kristina M. Utzschneider, MD, Jenny Tong, MD, MPH

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:  Beret Anne Casey, MD

The following SPC Committee members reported financial relationships:

  • Andjela T. Drincic, MD: Advisory Board Member, Corcept
  • Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
  • Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member
  • Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

Disclosure information for presenters is included in their individual recorded presentations.

The following SPC members reported no relevant financial relationships:

Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The staff involved in the development of this CME activity reported no relevant financial relationships.

DISCLAIMERS

USE OF PROFESSIONAL JUDGMENT:

The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This educational activity is supported by an independent medical educational grant from Novo Nordisk, Inc.

PLEASE CLICK "START" TO COMPLETE FOLLOW-UP SURVEY